- Home
- FLC vs ATLN Comparison
FLC vs ATLN Comparison
Compare FLC & ATLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- ATLN
- Stock Information
- Founded
- FLC 2003
- ATLN 2014
- Country
- FLC United States
- ATLN United States
- Employees
- FLC N/A
- ATLN N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- ATLN
- Sector
- FLC Finance
- ATLN
- Exchange
- FLC Nasdaq
- ATLN NYSE
- Market Cap
- FLC 176.2M
- ATLN 186.7M
- IPO Year
- FLC N/A
- ATLN 2021
- Fundamental
- Price
- FLC $17.03
- ATLN $2.50
- Analyst Decision
- FLC
- ATLN
- Analyst Count
- FLC 0
- ATLN 0
- Target Price
- FLC N/A
- ATLN N/A
- AVG Volume (30 Days)
- FLC 37.8K
- ATLN 20.3K
- Earning Date
- FLC 01-01-0001
- ATLN 01-01-0001
- Dividend Yield
- FLC 6.64%
- ATLN N/A
- EPS Growth
- FLC N/A
- ATLN N/A
- EPS
- FLC N/A
- ATLN N/A
- Revenue
- FLC N/A
- ATLN $429,260,149.00
- Revenue This Year
- FLC N/A
- ATLN N/A
- Revenue Next Year
- FLC N/A
- ATLN N/A
- P/E Ratio
- FLC N/A
- ATLN N/A
- Revenue Growth
- FLC N/A
- ATLN 5.50
- 52 Week Low
- FLC $12.62
- ATLN $1.30
- 52 Week High
- FLC $15.45
- ATLN $8.98
- Technical
- Relative Strength Index (RSI)
- FLC 51.43
- ATLN N/A
- Support Level
- FLC $16.93
- ATLN N/A
- Resistance Level
- FLC $17.19
- ATLN N/A
- Average True Range (ATR)
- FLC 0.17
- ATLN 0.00
- MACD
- FLC -0.00
- ATLN 0.00
- Stochastic Oscillator
- FLC 52.27
- ATLN 0.00
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.